NCT02978261View on ClinicalTrials.gov

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

April 30, 2018

Study Completion Date

December 31, 2018

Conditions

Glioma

Interventions

DRUG

PLB1001

PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.

Trial Locations (1)

100038

Beijing Shijitan Hospital,CMU, Beijing

All Listed Sponsors

lead

Beijing Pearl Biotechnology Limited Liability Company

INDUSTRY

NCT02978261 - Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas | Biotech Hunter | Biotech Hunter